Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placental mesenchymal stem cell-derived exosomes in hospitalized patients with COVID-19
IRCT20130812014333N164Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Dec 2020
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of placental mesenchymal stem cell-derived exosomes in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoints: Oxygen saturation, Neutrophil lymphocyte ratio and 1 more. Started Dec 2020; status: completed.
02
Drugs
placental mesenchymal stem cell-derived exosomes
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20130812014333N164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130812014333N164.